Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÖzdemir, Özlem
dc.contributor.authorZengel, Baha
dc.contributor.authorYıldız, Yaşar
dc.contributor.authorOyan Uluç, Başak
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorÖzden, Ercan
dc.contributor.authorKıvrak Salim, Derya
dc.contributor.authorPaydaş, Semra
dc.contributor.authorDemir, Atakan
dc.contributor.authorDiker, Ömer
dc.contributor.authorPilancı, Kezban Nur
dc.contributor.authorUysal Sönmez, Özlem
dc.contributor.authorVatansever, Sezai
dc.contributor.authorDoğan, İzzet
dc.contributor.authorGülmez, Ahmet
dc.contributor.authorÇakar, Burcu
dc.contributor.authorGürsoy, Pınar
dc.contributor.authorYıldırım, Mahmut Emre
dc.contributor.authorAyhan, Murat
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorAykan, Musa Barış
dc.contributor.authorÇevik, Gökçen Tuğba
dc.contributor.authorŞakalar, Teoman
dc.contributor.authorHacıbekiroğlu, İlhan
dc.contributor.authorBelen Gülbağcı, Burcu
dc.contributor.authorDinçer, Murat
dc.contributor.authorBayır Garbioğlu, Duygu
dc.contributor.authorKemal, Yasemin
dc.contributor.authorNayır, Erdinç
dc.contributor.authorTaşkaynatan, Halil
dc.contributor.authorYılmaz, Mesut
dc.contributor.authorAvcı, Okan
dc.contributor.authorSarı, Murat
dc.contributor.authorÇoban, Ezgi
dc.contributor.authorAtcı, Muhammed Mustafa
dc.contributor.authorAktürk Esen, Selin
dc.contributor.authorAkın Telli, Tuğba
dc.contributor.authorKarataş, Fatih
dc.contributor.authorİnal, Ali
dc.contributor.authorDemir, Hacer
dc.contributor.authorÖnal Kalkan, Nurhan
dc.contributor.authorYılmaz, Cengiz
dc.contributor.authorTaşlı, Funda
dc.contributor.authorAlacacıoğlu, Ahmet
dc.date.accessioned2022-06-16T07:04:32Z
dc.date.available2022-06-16T07:04:32Z
dc.date.issued07.06.2022en_US
dc.identifier.issn1473-5741
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000001310
dc.identifier.urihttps://hdl.handle.net/20.500.12933/1178
dc.description.abstractIn our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. The presence of DCIS in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.en_US
dc.language.isoengen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.relation.isversionof10.1097/CAD.0000000000001310en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleThe effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group studyen_US
dc.typearticleen_US
dc.authorid0000-0003-1235-9363en_US
dc.departmentAFSÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.contributor.institutionauthorDemir, Hacer
dc.relation.journalAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster